Carl Maximilian Thielmann

Carl Maximilian Thielmann

Auto-generated profile, based on publicly available information

Carl Maximilian Thielmann

Department of Dermatology, Venereology and Allergology University Hospital Essen, University School of Medicine Duisburg‐Essen Essen Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
CTCarl M. Thielmann
Carl M. Thielmann
ECEleftheria Chorti
Eleftheria Chorti
JMJohanna Matull
Johanna Matull
RMRajmohan Murali
Rajmohan Murali
AZAnne Zaremba
Anne Zaremba
KGKlaus G. Griewank
Klaus G. Griewank

10 March 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
GLGeorg Lodde
Georg Lodde
PJPhilipp Jansen
Philipp Jansen
IMInga Möller
Inga Möller
ASAntje Sucker
Antje Sucker
Jessica HasselJessica Hassel
Jessica Hassel
KGKlaus G. Griewank
Klaus G. Griewank

20 December 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
CTCarl M. Thielmann
Carl M. Thielmann
JMJohanna Matull
Johanna Matull
AZAnne Zaremba
Anne Zaremba
RMRajmohan Murali
Rajmohan Murali
ECEleftheria Chorti
Eleftheria Chorti
KGKlaus G. Griewank
Klaus G. Griewank

22 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CTCarl Maximilian Thielmann
Carl Maximilian Thielmann
JMJohanna Matull
Johanna Matull
SRSebastian Roth
Sebastian Roth
JPJan-Malte Placke
Jan-Malte Placke
ECEleftheria Chorti
Eleftheria Chorti
KGKlaus G. Griewank
Klaus G. Griewank
(1) Background: Melanoma has the highest mortality of all cutaneous tumors, despite recent treatment advances. Many relevant genetic events have been identified in the last decade, including recurrent ARID1A mutations, which in various tumors have been associated with improved outcomes to immunotherapy. (2) Methods: Retrospective analysis of 116 melanoma samples harboring ARID1A mutations. Assessment of clinical and genetic characteristics was performed as well as correlations with treatment outcome applying Kaplan–Meier (log-rank test), Fisher’s exact and Chi-squared tests. (3) Results: The majority of ARID1A mutations were in cutaneous and occult melanoma. ARID1A mutated samples had a higher number of mutations than ARID1A wild-type samples and harbored UV-mutations. A male predominance was observed. Many samples also harbored NF1 mutations. No apparent differences were noted between samples harboring genetically inactivating (frame-shift or nonsense) mutations and samples with other mutations. No differences in survival or response to immunotherapy of patients with ARID1A mutant melanoma were observed. (4) Conclusions: ARID1A mutations primarily occur in cutaneous melanomas with a higher mutation burden. In contrast to findings in other tumors, our data does not support ARID1A mutations being a biomarker of favorable response to immunotherapies in melanoma. Larger prospective studies would still be warranted.

25 March 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
AZAnne Zaremba
Anne Zaremba
GLGeorg Lodde
Georg Lodde
RMRajmohan Murali
Rajmohan Murali
MPManuel Philip
Manuel Philip
ICIoana Cosgarea
Ioana Cosgarea
KGKlaus G. Griewank
Klaus G. Griewank

3 March 2025 in European Journal of Cancer
Verified
Journal Article
Open access
PJPhilipp Jansen
Philipp Jansen
WGWolfgang Galetzka
Wolfgang Galetzka
CTCarl M. Thielmann
Carl M. Thielmann
RMRajmohan Murali
Rajmohan Murali
AZAnne Zaremba
Anne Zaremba
KGKlaus G. Griewank
Klaus G. Griewank
TERT promoter mutations are the most prevalent mutations in melanoma. In this study, we investigated clinical characteristics and survival after first line therapies in a cohort of melanoma patients with known TERT promoter (pTERT) mutation status. Sequencing data from 2013 to 2021 covering 29 genes and the pTERT status was assessed and 774 melanomas patients with known pTERT status and clinical data were analyzed. Progression free survival (PFS) and overall survival (OS) of 374 melanoma patients in AJCC-stage IV who received first-line immune checkpoint inhibitors (ICI, anti-CTLA4 /anti-PD1 combination therapy or anti-PD1 monotherapy) or targeted therapy (TT) were assessed applying Cox uni-/ multivariable analyses and Kaplan-Meier curves. The cohort included 573 cutaneous, 69 mucosal, 37 acral and 95 MUP (melanomas of unknown primary) melanoma patients with a median observational time from first diagnosis to patient death or censoring of 38.5 months. TERT promoter mutations were identified in 476 melanomas (61.5 %). Survival analysis of 374 patients with stage IV disease undergoing first-line systemic therapy (ICI or TT) suggested prolonged PFS and OS for patients with pTERT mutation positive tumors (pTERT(+)). Particularly, pTERT(+) patients receiving anti-CTLA4/anti-PD1 therapy showed mPFS of 14.8 months (95 % CI: 7.1-40.3) and mOS of 105.2 months (95 % CI: 27.6-not reached) compared to pTERT(-) patients with mPFS of 5.5 months (95 % CI: 2.7-10.0) and mOS of 14.7 months (95 % CI: 11.7-24.1). Our findings suggest that presence of a pTERT mutation in melanomas might favor PFS and OS after first line ICI with the greatest improvement after receiving anti-CTLA4 / anti-PD1. If validated in larger prospective studies, pTERT mutation status may be a valuable prognostic marker for stage IV melanoma patients.